Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data
Erişim
info:eu-repo/semantics/closedAccessTarih
2022Yazar
Karadurmuş, NuriYıldırım, Emre
Yalçın, Şuayib
Gümüş, Mahmut
Bilir, Cemil
Çubukçu, Erdem
Tanrıkulu Şimşek, Eda
Arslan, Çağatay
Dane, Faysal
Çelik, Sinemiş
Bilici, Ahmet
Şendur, Mehmet Ali Nahit
Öven, Başak Bala
Işıkdoğan, Abdurrahman
Türk, Hacı Mehmet
Karaca, Mustafa
Karabulut, Bülent
Özçelik, Melike
Çevik, Duygu
Kefeli, Umut
Üst veri
Tüm öğe kaydını gösterKünye
Karadurmuş, N., Yıldırım, E., Yalçın, Ş., Gümüş, M., Bilir, C., Çubukçu, E. ... Kefeli, U. (2022). Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2022.40.4_suppl.299Özet
Background: The contribution of metastasectomy to progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced stage colorectal cancer has been demonstrated in clinical trials. However, clinical trials may not represent the efficacy of treatment given to the whole population in daily practice, therefore evaluation of real-life data is needed. Methods: The demographic, pathological and clinical characteristics of 1064 RAS wild type pts were recorded in 28 centers in Turkey between January 2016 and March 2019 as part of the Onco-Colon Registry Program (NCT04757311). Metastasectomy was performed in 169 patients (15.9%). In this study, pts with and without metastasectomy were compared in terms of demographic, histopathological and clinical features and treatment results. Results: Median follow-up time was 24 months(mos) (1-74), median age was 59 years (30-81). 32.5% of the pts were women. The proportion of pts with primary right colon was determined to be 16.8%. Synchronous metastasis was detected in 76.3% of those who underwent metastasectomy. Isolated liver metastasectomy was performed in 85.8% of the pts. It has been shown that 21.1% of the pts have MSI-H and 23.3% have a mucinous component. Metastasectomy was performed after conversion therapy in 54.8% of pts. In the patient group who underwent metastasectomy after medical treatment, the median time between the beginning of treatment and metastasectomy was found to be 7 mos (2-34). When the patient characteristics were compared, no significant difference was found between the groups with and without metastasectomy (p > 0.05). The median PFS (mPFS) was 13.5 mos in the group that underwent metastasectomy and 9.9 mos in the group that was not performed (p < 0.0001; HR: 0.63 (95% CI: 0.51-0.77). The median OS (mOS) was 47.3 mos in the group that underwent metastasectomy and 24.3 mos in the group without metastasectomy (p < 0.0001; HR: 0.36 (95% CI: 0.27-0.48). Conclusions: The significant contribution of metastasectomy on mPFS and mOS was shown in this reallife data based trial, where no difference was found in terms of general participation characteristics. In daily practice, prolonged mPFS and mOS emerges as pts who are followed-up radiologically at regular intervals from the beginning and who are appropriate for surgery have the chance of metastasectomy.
WoS Q Kategorisi
Q1Kaynak
Journal of Clinical OncologyCilt
40Sayı
4Koleksiyonlar
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6696]